Sangamo Therapeutics (NASDAQ: SGMO) closed down 10.5% while bluebird bio (NASDAQ: BLUE) slipped 4.8% after competitor Global Blood Therapeutics (NASDAQ: GBT) reported positive data for its sickle cell disease drug, voxelotor.In the part A of Global Blood's phase 3 study, 58% of patients taking the higher dose of voxelotor reached the pre-defined goal of a 1 g/dL increase in hemoglobin, while 38% of the patients taking the lower dose reached the goal, compared to just 9% of patients taking placebo.But that's not even the worse news for Sangamo and Bluebird.Continue reading